Literature DB >> 29799974

Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia.

Melissa K Accordino1,2, Jason D Wright2,3, Sowmya Vasan4, Donna L Buono4, Jim C Hu5, Alfred I Neugut1,2,4, Dawn L Hershman1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29799974      PMCID： PMC6145730          DOI： 10.1001/jamaoncol.2018.0818

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Overriding of drug safety alerts in computerized physician order entry.

Authors:  Heleen van der Sijs; Jos Aarts; Arnold Vulto; Marc Berg
Journal:  J Am Med Inform Assoc       Date:  2005-12-15       Impact factor: 4.497

2.  Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

Authors:  Otavio A C Clark; Gary H Lyman; Aldemar A Castro; Luciana G O Clark; Benjamin Djulbegovic
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

3.  A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.

Authors:  Aasthaa Bansal; Sean D Sullivan; Dawn L Hershman; Gary H Lyman; William E Barlow; Jeannine S McCune; Scott D Ramsey
Journal:  J Comp Eff Res       Date:  2017-07-07       Impact factor: 1.744

Review 4.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Thomas J Smith; Kari Bohlke; Gary H Lyman; Kenneth R Carson; Jeffrey Crawford; Scott J Cross; John M Goldberg; James L Khatcheressian; Natasha B Leighl; Cheryl L Perkins; George Somlo; James L Wade; Antoinette J Wozniak; James O Armitage
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

5.  Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.

Authors:  Jason D Wright; Alfred I Neugut; Cande V Ananth; Sharyn N Lewin; Elizabeth T Wilde; Yu-Shiang Lu; Thomas J Herzog; Dawn L Hershman
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.